Can BCLC-B patients benefit from systemic therapy?
9.30 pm (NZDT) for New Zealand viewers
Presenter
Professor Jeff Evans (Scotland, UK)
Director of the Institute of Cancer Sciences and lead of the Glasgow Experimental Cancer Medicine Centre, and a Professor of Translational Cancer Research.
Chairperson
Dr Richard Skoien
Hepatologist, Royal Brisbane and Women's Hospital, Queensland Australia.
This is an Eisai-sponsored promotional meeting and is for healthcare professionals only. By registering for this event, you are declaring that you are a healthcare professional.
Australian Attendees
Lenvima® is a registered trademark of the Eisai Group, whose affiliate company in Australia is Eisai Australia Pty Ltd, Level 2, 437 St Kilda Road, Melbourne VIC 3004. ABN 73 117 970 993.
Contact Eisai Australia Medical Information on 03 9832 9100 or medinfo_australia@eisai.net. Adverse Events can also be reported to safety_australia@eisai.net.
Privacy Statement: Eisai Australia Pty Ltd (“Eisai”) are committed to protecting your privacy. Eisai will handle personal information about you in accordance with the Privacy Act 1988 (Cth). More information about the way Eisai handle personal information is set out in our privacy policy, which is available at www.eisai.com.au/privacy-policy/.
If you do not wish to receive further information regarding Eisai educational events or products, please email contact_australia@eisai.net. Eisai Australia Pty Ltd, Level 2, 437 St Kilda Road, Melbourne, VIC 3004. By registering for this webinar you are agreeing to be contacted regarding this webinar only.
Date of preparation February 2023 AU-LENB-23-00002
New Zealand Attendees
Lenvima® (lenvatinib mesilate) – Prescription Medicine, unfunded (prescription charge will apply). Available in 4 mg and 10 mg hard capsules. For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). Before prescribing Lenvima review the Data Sheet for information on dosage, contraindications, precautions, interactions and adverse effects, available at www.medsafe.govt.nz. Date of most recent amendment: June 2022.
Lenvima® is a registered trademark of the Eisai Group, whose affiliate company in New Zealand is Eisai New Zealand Limited, c/o, Simpson Grierson, Level 27, 88 Shortland Street, Auckland Central, Auckland, 1010.
TAPS DA2263MR
Contact Eisai New Zealand Medical Information: +613 9832 9100 or medinfo_newzealand@eisai.net. Adverse Events can also be reported to safety_newzealand@eisai.net
Privacy Statement: We are committed to protecting your privacy. We will handle personal information about you in accordance with Eisai’s obligations under the Privacy Act 2020 (“Privacy Act”), and the Health Information Privacy Code (“HIPC”). More information about the way we handle personal information is set out in our privacy policy, which is available at www.eisai.co.nz/privacy-policy/
If you do not wish to receive further information regarding Eisai educational events or products, please email contact_NewZealand@eisai.net. By registering for this webinar you are agreeing to be contacted regarding this webinar only.
